coronary heart disease patients 1188
drug choice/monitoring 2200 – – 11
drug interactions 23
secondary prevention of acute
myocardial infarction 63–4
side effects 2222 – – 33
LIPID study 18
liver function, effect of lipid-lowering
therapy 22
long QT syndrome 117755 – – 66 , 177
Long-Term Intervention with
Pravastatin in Ischaemic
Disease (LIPID) Study 18
losartan, heart failure 112
magnesium sulphate, intravenous,
hypertensive encephalopathy in
pre-eclampsia 16
magnetic resonance imaging (MRI),
pacemaker patients 168
methyldopa, malignant hypertension
15
methylprednisolone, transplant
patients 129
Metoprolol CR/XL Randomised
Intervention Trial in Heart
Failure (MERIT-HF) 118
milrinone 115
mitral regurgitation, surgery for 8877 – – 88 ,
89
mitral stenosis, pregnancy 196
mitral valve repair 8899 – – 9911
mycophenolate mofetil, transplant
patients 129–30
myocardial infarction (MI)
ACE-inhibitor treatment of impaired
ventricular function 111–12
angioplasty in 5555 – – 66
cardiogenic shock and 6688 – – 99 , 95–6
driving and flying after 6666 – – 77
effect of recent MI on perioperative
risks of CABG 8844 – – 55
exercise testing after 5599 – – 6600
risk, at time of cardiac surgery 7700 – – 11
risks of recurrent ischaemic events
6611 – – 22
secondary prevention after 6633 – – 55
septal rupture following 7722
thrombolytic therapy 5511 – – 44
contraindications 5577 – – 88
unstable angina and 4411 – – 22
ventricular septal defect following
95–6
myocardial perfusion imaging (MPI)
3311 – – 22
myocardium, hibernating/stunned
3333 – – 44
myositis, lipid-lowering therapy and
22, 23neuropsychological complications,
cardiopulmonary bypass 7799 – – 8811
New York Heart Association
functional capacity score, heart
failure prognosis 112200 – – 22
nicorandil, angina 35
nifedipine
contraindication 43
malignant hypertension 15
hypertension treatment,
cardiovascular risks 12
nimodipine, malignant hypertension
16
nitrates
angina 35
unstable 43
chronic heart failure 114OKT3, transplant patients 129
Organisation to Assess Strategies for
Ischaemic Syndromes (OASIS)
Registry 41, 45–6pacemakers
and cardioversion 117700
external magnetic interference 116688 – – 99
insertion risks 116666 – – 77
VVI/dual chamber, prescription
gudelines 116666 – – 77
pacing
hypertrophic cardiomyopathy 110055
trifascicular disease 116644 – – 55
paclitaxel 48
PAMI trial 55
percutaneous transluminal coronary
angioplasty (PTCA)
myocardial infarction 5555 – – 66
complicated by cardiogenic shock
68, 69
restenosis prevention following
4488 – – 5500
unstable angina patients 4455 – – 77
phones, mobile, pacemaker patients
168–9
photodynamic therapy (PTD),
prevention of restenosis
following PTCA 49
plasminogen activator, recombinant
(r-PA) 53
positron emission tomography (PET),
assessment of myocardial
viability 33–4
PRAISE studies 114
pravastatin, LIPID study 18220 Index